Milk allergy immunotherapy - DBV Technologies

Drug Profile

Milk allergy immunotherapy - DBV Technologies

Alternative Names: Viaskin Milk

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DBV Technologies
  • Developer DBV Technologies; The Childrens Hospital of Philadelphia
  • Class Food allergy immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Eosinophilic oesophagitis; Milk hypersensitivity

Most Recent Events

  • 26 Feb 2018 Preliminary efficacy and adverse events data from a phase I/II MILES trial in Milk hypersensitivity released by DBV Technologies
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Milk-hypersensitivity(In children) in France (Topical, Patch)
  • 08 Nov 2016 DBV Technologies completes enrolment in the phase II or Part B portion of the phase I/II MILES study for Milk hypersensitivity in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top